Market Overview

Looking Into Regeneron Pharmaceuticals's Return On Capital Employed


Regeneron Pharmaceuticals (NASDAQ: REGN) posted a 6.24% decrease in earnings from Q1. Sales, however, increased by 6.78% over the previous quarter to $1.95 billion. Despite the increase in sales this quarter, the decrease in earnings may suggest Regeneron Pharmaceuticals is not utilizing their capital as effectively as possible. Regeneron Pharmaceuticals reached earnings of $700.10 million and sales of $1.83 billion in Q1.

What Is Return On Capital Employed?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Regeneron Pharmaceuticals posted an ROCE of 0.07%.

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

Return on Capital Employed is an important measurement of efficiency and a useful tool when comparing companies that operate in the same industry. A relatively high ROCE indicates a company may be generating profits that can be reinvested into more capital, leading to higher returns and growing EPS for shareholders.

In Regeneron Pharmaceuticals's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions.

Q2 Earnings Recap

Regeneron Pharmaceuticals reported Q2 earnings per share at $7.16/share, which beat analyst predictions of $5.98/share.


Related Articles (REGN)

View Comments and Join the Discussion!

Posted-In: Earnings News Health Care General